An ongoing dialogue on HIV/AIDS, infectious diseases,
December 28th, 2011
Why We Still Need HIV/ID Specialists
Over on Journal Watch AIDS Clinical Care, we periodically publish a tricky case — always drawn from clinical practice — then ask some experts how they would manage it, and why.
The most recent case pretty much has it all:
- Multiple prior regimens
 - Multi-class drug resistance
 - Metabolic complications
 - Bad allergy history, one event nearly requiring hospitalization
 - Disfiguring lipoatrophy
 - History of treatment discontinuation
 
In fact, the case is so complicated that our Executive Editor said it made her “head hurt.” She’s just lucky the guy doesn’t have hepatitis C.
Fortunately, Graeme Moyle and Karam Mounzer kindly agreed to take it on. Given the complexity of the case, not surprisingly they came up with two different treatment approaches.
And patients like this are a reminder why, even in this era of single-pill-daily-for-HIV-treatment and 80-90% of patients in care virologically suppressed, we HIV/ID specialists still have a job.
                    Categories: Antiretroviral Rounds, HIV, Patient Care                    
                                        
                You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch 
Infectious Diseases 
      
      Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
- 			
 - 
		
From the Blog — Most Recent Articles
- Two Covid Vaccine Studies — One Actionable, the Other Not So Much October 28, 2025
 - What a Difference a Year Makes — with Bonus Halloween Video October 23, 2025
 - Another Bad Week for the CDC, and a Personal Note October 16, 2025
 - DOTS: Optimism Around a “Negative” Dalbavancin Trial October 10, 2025
 - Update on Louie and One Interesting ID Fact October 3, 2025
 
 
 NEJM Journal Watch — Recent Infectious Disease Articles- Effectiveness of the 2024–2025 Covid-19 Vaccines Examined
 - Real-World Performance of Zoster Vaccine
 - Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
 - Observations from ID and Beyond: What a Difference a Year Makes — with Bonus Halloween Video
 - RSV Vaccination in Stem-Cell Transplant Recipients
 
- 
        			
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
 
 
